Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Borbath

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
Gut|June 3, 2019
<i>Kras</i> and <i>Lkb1</i> mutations synergistically induce intraductal papillary mucinous neoplasm derived from pancreatic duct cellsLouis Collet, Elsa Ghurburrun, Nora Meyers, et al.
Journal of Neuroendocrinology|November 28, 2024
Neuroendocrine tumors in the stomach: An epidemiological analysis of Belgian Cancer Registry data 2010-2019Marlies Maly, Eduard Callebout, Suzane Ribeiro, et al.
British Journal of Cancer|November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined responseAngela Lamarca, Jorge Barriuso, Matthew Kulke, et al.
Acta Clinica Belgica|October 5, 2021
Quality of pathology reporting and adherence to guidelines in rectal neuroendocrine neoplasms: a Belgian national studyBruno Waked, Filip De Maeyer, Saskia Carton, et al.
Journal of the National Cancer Institute|January 29, 2017
Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine CarcinomasAngela Lamarca, Thomas Walter, Marianne Pavel, et al.
JAMA|May 4, 2016
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical TrialPascal Hammel, Florence Huguet, Jean-Luc van Laethem, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2022
The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasmsIvan Borbath, Rocio Garcia-Carbonero, Damir Bikmukhametov, et al.
Neuroendocrinology|April 14, 2017
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin AnaloguesRodney J Hicks, Dik J Kwekkeboom, Eric Krenning, et al.
Hepatic Oncology|September 8, 2018
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trialLorenza Rimassa, Camillo Porta, Ivan Borbath, et al.
Neuroendocrinology|February 13, 2017
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic StratificationAurel Perren, Anne Couvelard, Jean-Yves Scoazec, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Gut|June 3, 2019
<i>Kras</i> and <i>Lkb1</i> mutations synergistically induce intraductal papillary mucinous neoplasm derived from pancreatic duct cellsLouis Collet, Elsa Ghurburrun, Nora Meyers, et al.
Journal of Neuroendocrinology|November 28, 2024
Neuroendocrine tumors in the stomach: An epidemiological analysis of Belgian Cancer Registry data 2010-2019Marlies Maly, Eduard Callebout, Suzane Ribeiro, et al.
British Journal of Cancer|November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined responseAngela Lamarca, Jorge Barriuso, Matthew Kulke, et al.
Acta Clinica Belgica|October 5, 2021
Quality of pathology reporting and adherence to guidelines in rectal neuroendocrine neoplasms: a Belgian national studyBruno Waked, Filip De Maeyer, Saskia Carton, et al.
Journal of the National Cancer Institute|January 29, 2017
Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine CarcinomasAngela Lamarca, Thomas Walter, Marianne Pavel, et al.
JAMA|May 4, 2016
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical TrialPascal Hammel, Florence Huguet, Jean-Luc van Laethem, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2022
The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasmsIvan Borbath, Rocio Garcia-Carbonero, Damir Bikmukhametov, et al.
Neuroendocrinology|April 14, 2017
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin AnaloguesRodney J Hicks, Dik J Kwekkeboom, Eric Krenning, et al.
Hepatic Oncology|September 8, 2018
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trialLorenza Rimassa, Camillo Porta, Ivan Borbath, et al.
Neuroendocrinology|February 13, 2017
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic StratificationAurel Perren, Anne Couvelard, Jean-Yves Scoazec, et al.
Pageof 9